Zevra announces publication of miplyffa® mechanism of action manuscript in molecular genetics and metabolism

Celebration, fla., april 17, 2025 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) (zevra, or the company), a commercial-stage company focused on providing therapies for people living with rare disease, today announces the publication of “mechanistic insights into arimoclomol mediated effects on lysosomal function in niemann-pick type c disease” in molecular genetics and metabolism.
ZVRA Ratings Summary
ZVRA Quant Ranking